<?xml version="1.0" encoding="UTF-8"?>
<ref id="B90">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kawashima</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Nemoto</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Honda</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Watanabe</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Nakayama</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Imafuku</surname>
    <given-names>S.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2017</year>). 
  <article-title>Amenamevir, a novel helicase–primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study.</article-title>
  <source>
   <italic>J. Dermatol.</italic>
  </source>
  <volume>44</volume>
  <fpage>1219</fpage>–
  <lpage>1227</lpage>. 
  <pub-id pub-id-type="doi">10.1111/1346-8138.13948</pub-id>
  <?supplied-pmid 28681394?>
  <pub-id pub-id-type="pmid">28681394</pub-id>
 </mixed-citation>
</ref>
